Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8IXW5
UPID:
RPAP2_HUMAN
Alternative names:
RNA polymerase II-associated protein 2
Alternative UPACC:
Q8IXW5; C9JKB5; Q49AS7; Q9H8Y2
Background:
The Putative RNA polymerase II subunit B1 CTD phosphatase RPAP2, also known as RNA polymerase II-associated protein 2, plays a crucial role in the transcription regulation of snRNA genes. It specifically targets the CTD of POLR2A, facilitating transcription by dephosphorylating 'Ser-5'. Additionally, RPAP2 is involved in the endoplasmic reticulum unfolded protein response by dephosphorylating ERN1, thus influencing apoptosis.
Therapeutic significance:
Understanding the role of Putative RNA polymerase II subunit B1 CTD phosphatase RPAP2 could open doors to potential therapeutic strategies.